Recent developments in the management of invasive fungal infections in patients with hematological malignancies.
Despite recent advances in the last decade, invasive fungal infections are still associated with a high morbidity and mortality. Invasive fungal infections constitute severe infectious complications in patients with hematological malignancies receiving myelosuppressive chemotherapy or sustained immunosuppression after allogeneic transplant regimens. Following a long period of stagnation, considerable progress has been made during the last 5 years in non-culture-based diagnostics and in the treatment of invasive fungal infections. This review highlights recent developments in the epidemiology, diagnosis, and treatment in the context of state-of-the-art management of invasive fungal infections in cancer patients.
Karthaus
Meinolf
M
Medizinische Klinik II, Evangelisches Johannes-Krankenhaus, Schildescher Strasse 99, 33611 Bielefeld, Germany. Meinolf-Karthaus@johanneswerk.de
Cornely
Oliver A
OA
D019468:Disease Management; D025141:Drug Resistance, Fungal; D019337:Hematologic Neoplasms / Q000150:complications* / Q000628:therapy; D006801:Humans; D009181:Mycoses / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D009894:Opportunistic Infections; D011292:Premedication